Skip to content
10-Q

Quarterly Report

Viridian Therapeutics, Inc.\DE VRDN

0001590750-25-000020

← back to feed
Filed
Nov 5, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Oct 31, 2025 95.44M sh
Capex Q3 2025 · Sep 30, 2025 $255K
Capex Q3 2025 · Sep 30, 2024 $397K
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$252.64M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$158.99M
Long Term Debt Q3 2025 · Sep 30, 2025 $20.89M
Long Term Debt Q3 2025 · Dec 31, 2024 $20.58M
Stockholders Equity Q3 2025 · Sep 30, 2025 $502.97M
Stockholders Equity Q3 2025 · Jun 30, 2025 $515.17M
Stockholders Equity Q3 2025 · Mar 31, 2025 $604.47M
Stockholders Equity Q3 2025 · Dec 31, 2024 $671.64M
Stockholders Equity Q3 2025 · Sep 30, 2024 $707.5M
Stockholders Equity Q3 2025 · Jun 30, 2024 $529.34M
Stockholders Equity Q3 2025 · Mar 31, 2024 $582.53M
Stockholders Equity Q3 2025 · Dec 31, 2023 $442.02M
Current Liabilities Q3 2025 · Sep 30, 2025 $50.7M
Current Liabilities Q3 2025 · Dec 31, 2024 $47.87M
Total Liabilities Q3 2025 · Sep 30, 2025 $74.17M
Total Liabilities Q3 2025 · Dec 31, 2024 $70.76M
Current Assets Q3 2025 · Sep 30, 2025 $571.91M
Current Assets Q3 2025 · Dec 31, 2024 $738.46M
Total Assets Q3 2025 · Sep 30, 2025 $577.14M
Total Assets Q3 2025 · Dec 31, 2024 $742.4M
Net Income Q3 2025 · Sep 30, 2025 −$34.6M
Net Income Q3 2025 · Sep 30, 2025 −$222.25M
Net Income Q3 2025 · Jun 30, 2025 −$100.74M
Net Income Q3 2025 · Mar 31, 2025 −$86.91M
Net Income Q3 2025 · Sep 30, 2024 −$76.69M
Net Income Q3 2025 · Sep 30, 2024 −$190.22M
Net Income Q3 2025 · Jun 30, 2024 −$64.99M
Net Income Q3 2025 · Mar 31, 2024 −$48.54M
Operating Income Q3 2025 · Sep 30, 2025 −$40.01M
Operating Income Q3 2025 · Sep 30, 2025 −$240.65M
Operating Income Q3 2025 · Sep 30, 2024 −$83.48M
Operating Income Q3 2025 · Sep 30, 2024 −$211.56M
Shares Diluted Q3 2025 · Sep 30, 2024 66.42M sh
Shares Diluted Q3 2025 · Sep 30, 2024 63.8M sh